Why the study?
Does erythropoietin improve left ventricular ejection fraction after 6 months in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention?
RCT (n=138)
Double-blind
Randomized
Does erythropoietin improve left ventricular ejection fraction after 6 months in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Short-term intravenous erythropoietin treatment during primary PCI for acute STEMI does not improve left ventricular ejection fraction or clinical outcomes at 6 months.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2012 study conducted an RCT in Acute ST-Segment-Elevation Myocardial Infarction (n=138). Erythropoietin vs. Placebo was evaluated on Left ventricular ejection fraction after 6 months, measured by MRI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: